---
layout: post
title: New Drug Approvals 2012 - Pt. XIII - Lorcaserin hydrochloride (Belviqâ„¢)
date: '2012-06-29T07:52:00.001+01:00'
author: Rita
tags:
- Small Molecule Drugs
- GPCRs
- 2012 New Drugs
modified_time: '2013-01-02T09:41:45.567Z'
thumbnail: http://1.bp.blogspot.com/-tBoHcpYSxpI/T-w0m0-zBII/AAAAAAAAA0Y/lgeE9V9LSRg/s72-c/lorcaserin.tif
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-478862270858207380
blogger_orig_url: http://chembl.blogspot.com/2012/06/new-drug-approvals-2012-pt-xiii.html
---

<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<center face="arial">
<img src="https://www.ebi.ac.uk/chembltools/autoiconlarge/1,1,0,1,0,0,1,0,0" width="400" /></center>
<br />
<br />
<div style="text-align: center;">
<b>ATC Code:</b> <a href="http://www.whocc.no/atc_ddd_index/?code=A08A">A08A</a> (incomplete)<br />
<b>Wikipedia:</b> <a href="http://en.wikipedia.org/wiki/Lorcaserin">Lorcaserin</a><br />
<br /></div>
<div style="text-align: justify;">
On June 27<sup>th</sup>, the FDA approved Lorcaserin hydrochloride (Tradename: <a href="http://www.trademarkia.com/belviq-85354490.html">Belviq</a><sup>TM</sup>; Research Code: APD-356), a selective <a href="http://en.wikipedia.org/wiki/5-HT2C_receptor">serotonin 2C receptor</a>&nbsp;(5HT2c) agonist, for chronic weight management in adults with an initial body mass index (<a href="http://en.wikipedia.org/wiki/Body_mass_index">BMI</a>) equal or higher than 30 kg/m<sup>2</sup> (obese), or equal or higher than 27 kg/m<sup>2</sup> (overweight) and with one weight-associated comorbid condition (e.g. <a href="http://en.wikipedia.org/wiki/Hypertension">hypertension</a>, <a href="http://en.wikipedia.org/wiki/Dyslipidemia">dyslipidemia</a>, <a href="http://en.wikipedia.org/wiki/Type_2_diabetes">type 2 diabetes</a>).</div>
<br />
<div style="text-align: justify;">
Lorcaserin is believed to decrease food consumption and promote satiety by selectively activating 5-HT<sub>2C</sub> receptors on anorexigenic <a href="http://en.wikipedia.org/wiki/Proopiomelanocortin">pro-opiomelanocortin</a> neurones in the hypothalamus. The exact mechanism of action is not fully established. However, at therapeutic concentrations, lorcaserin is selective for 5-HT<sub>2C</sub> receptors as compared to 5-HT<sub>2B</sub> receptors, making it less prone to cardiovascular side-effects, associated with previous&nbsp;5-HT<sub>2C</sub>&nbsp;weight management drugs. It is the first anti-obesity drug to be approved after the withdraw of <a href="http://en.wikipedia.org/wiki/Dexfenfluramine">Dexfenfluramine</a> in 1997. Given the safety issues of previous drugs, the development has focussed on safety, and with the data in hand, lorcaserin has been approved without a boxed warning.</div>
<br />
<div style="text-align: justify;">
The <a href="http://en.wikipedia.org/wiki/5-HT2C_receptor">5-HT<sub>2C</sub> receptor</a> (Uniprot: <a href="http://www.uniprot.org/uniprot/P28335">P28335</a>, ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/index.php/target/inspect/CHEMBL225">CHEMBL225</a>) belongs to the G-protein coupled receptor (GPCR) type 1 family, and binds the endogenous neurotransmitter <a href="http://en.wikipedia.org/wiki/Serotonin">serotonin</a>. Its activation inhibits dopamine and norepinephrine release. <br />
<br />
<pre>&gt;5HT2C_HUMAN 5-hydroxytryptamine receptor 2C
MVNLRNAVHSFLVHLIGLLVWQCDISVSPVAAIVTDIFNTSDGGRFKFPDGVQNWPALSI
VIIIIMTIGGNILVIMAVSMEKKLHNATNYFLMSLAIADMLVGLLVMPLSLLAILYDYVW
PLPRYLCPVWISLDVLFSTASIMHLCAISLDRYVAIRNPIEHSRFNSRTKAIMKIAIVWA
ISIGVSVPIPVIGLRDEEKVFVNNTTCVLNDPNFVLIGSFVAFFIPLTIMVITYCLTIYV
LRRQALMLLHGHTEEPPGLSLDFLKCCKRNTAEEENSANPNQDQNARRRKKKERRPRGTM
QAINNERKASKVLGIVFFVFLIMWCPFFITNILSVLCEKSCNQKLMEKLLNVFVWIGYVC
SGINPLVYTLFNKIYRRAFSNYLRCNYKVEKKPPVRQIPRVAATALSGRELNVNIYRHTN
EPVIEKASDNEPGIEMQVENLELPVNPSSVVSERISSV
</pre>
</div>
<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://1.bp.blogspot.com/-tBoHcpYSxpI/T-w0m0-zBII/AAAAAAAAA0Y/lgeE9V9LSRg/s1600/lorcaserin.tif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="124" src="http://1.bp.blogspot.com/-tBoHcpYSxpI/T-w0m0-zBII/AAAAAAAAA0Y/lgeE9V9LSRg/s200/lorcaserin.tif" width="200" /></a></div>
<br />
<div style="text-align: justify;">
Lorcaserin (IUPAC: (5R)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; Canonical smiles: C[C@H]1CNCCc2ccc(Cl)cc12; PubChem: <a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11658860&amp;loc=ec_rcs">11658860</a>; Chemspider: <a href="https://www.chemspider.com/Chemical-Structure.9833595.html?rid=dac62ee4-2bb0-45a0-ab11-bc80c2b55fab">9833595</a>; ChEMBLID: <a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL360328">CHEMBL360328</a>; Standard InChI Key: XTTZERNUQAFMOF-QMMMGPOBSA-N) is a <a href="http://en.wikipedia.org/wiki/Benzazepines">benzazepine</a> with a single chiral center, with a molecular weight of 195.7 Da, 1 hydrogen bond acceptor, 1 hydrogen bond donor, and has an ALogP of 2.75. The compound is therefore fully rule-of-five compliant.</div>
<br />
<div style="text-align: justify;">
Lorcaserin is available as film-coated oral tablets of 10 mg, and the recommend daily dose is 20mg. The plasma half-life of lorcaserin (t<sub>1/2</sub>) is approximately 11 hr, and is moderately bound (~70%) to human plasma proteins. The absolute bioavailability of lorcaserin has not been reported.</div>
<br />
<div style="text-align: justify;">
Lorcaserin is extensively metabolised in the liver by multiple enzymatic pathways, however it inhibits CYP2D6, and therefore an increase in exposure of CYP 2D6 substrates may occur. The two major metabolites are lorcaserin sulfamate, and N-carbamoyl glucuronide lorcaserin. <br />
<br />
As a serotonergic drug, patients should be monitored for the emergence of <a href="http://en.wikipedia.org/wiki/Serotonin_syndrome">serotonin syndrome</a>. For the full list of adverse reactions and drug-drug interactions please refer to the full prescribing information.</div>
<br />
<div style="text-align: justify;">
The license holder for Belviq<sup>TM</sup> is <a href="http://www.arenapharm.com/">Arena Pharmaceuticals</a>, and the full prescribing information can be found <a href="http://us.eisai.com/package_inserts/BelviqPI.pdf">here</a>.</div>
